Meta-analysis of Genome wide Association Studies on Childhood ADHD Symptoms and Diagnosis Reveals 17 Novel Loci and 22 Potential Effector Genes

6

7 Van der Laan, Camiel M.^{1,2}, Ip, Hill F.¹, Schipper, Marijn³, Hottenga, Jouke-Jan¹, Krapohl, Eva M. L.⁴,Brikell, Isabell⁵, Soler Artigas, María^{6,7,8}, Cabana-Domínguez, Judith^{6,7,8}, Llonga 8 Natalia^{6,7,8}, Nolte, Ilja M.⁹, St Pourcain, Beate^{10,11,12}, Bolhuis, Koen¹³, Palviainen, Teemu¹⁴, 9 Zafarmand, Hadi^{15,16}, Gordon, Scott¹⁷, Zayats, Tetyana^{18,19,20}, Aliev, Fazil²¹, Burt, Alexandra S.²², 10 Wang, Carol A.^{23,24}, Saunders, Gretchen²⁵, Karhunen, Ville^{26,27}, Adkins, Daniel E.^{28,29}, Border, 11 Richard³⁰, Peterson, Roseann E.^{31,32}, Prinz, Joseph A.³³, Thiering, Elisabeth^{34,35}, Vilor-Tejedor, 12 Natàlia³⁶⁻³⁹, Ahluwalia, Tarunveer S.^{40,41}, Allegrini, Andrea⁴, Rimfeld, Kaili⁴, Chen, Qi⁵, Lu, Yi⁵, 13 Martin, Joanna⁵, Bosch, Rosa^{42,6}, Ramos Quiroga, Josep Antoni^{6,43,7,8}, Neumann, Alexander¹³, 14 Ensink, Judith^{44,45,46,47}, Grasby, Katrina¹⁷, Morosoli, José J.^{48,49,50}, Tong, Xiaoran⁵¹, Marrington, 15 Shelby⁵², Scott, James G.^{53,54,55}, Shabalin, Andrey A.²⁹, Corley, Robin⁵⁶, Evans, Luke M.^{56,57}, 16 Sugden, Karen^{58,32}, Alemany, Silvia^{6,7,8}, Sass, Lærke³⁹, Vinding, Rebecca³⁹, Ehli, Erik A.⁵⁹, 17 Hagenbeek, Fiona A.^{1,14,45}, Derks, Eske⁶⁰, Larsson, Henrik^{5,61}, Snieder, Harold⁹, Cecil, 18 Charlotte^{13,62,63}, Whipp, Alvce M.¹⁴, Korhonen, Tellervo¹⁴, Vuoksimaa, Eero¹⁴, Rose, Richard J.⁶⁴, 19 Uitterlinden, André G.^{63,65,66}, Haavik, Jan¹⁸, Harris, Jennifer R.⁶⁷, Helgeland, Øyvind⁶⁸, Johansson, 20 Stefan⁶⁹, Knudsen, Gun Peggy S.⁶⁷, Njolstad, Pal Rasmus⁶⁹, Lu, Qing⁷⁰, Rodriguez, Alina²⁶, 21 Henders, Anjali K.⁷¹, Mamun, Abdullah⁷², Najman, Jackob M.⁵², Brown, Sandy⁷³, Hopfer, 22 Christian⁷⁴, Krauter, Kenneth⁷⁵, Reynolds, Chandra^{76,57}, Smolen, Andrew⁵⁷, Stallings, Michael^{57,77}, 23 Wadsworth, Sally⁵⁷, Wall, Tamara⁷³, Eaves, Lindon^{78,32}, Silberg, Judy L. ^{78,32}, Miller, Allison⁷⁹, 24 Havdahl, Alexandra^{80,81}, Llop, Sabrina^{82,83}, Lopez-Espinosa, Maria-Jose^{82,83,84}, Bønnelykke, 25 Klaus⁴⁰, Sunyer, Jordi^{85,86,87}, Arseneault, Louise⁸⁸, Standl, Marie³⁴, Heinrich, Joachim^{34,89,90}, 26 27 Boden, Joseph⁹¹, Pearson, John⁹², Horwood, John⁹¹, Kennedy, Martin⁹³, Poulton, Richie⁹⁴, Maes, Hermine H.^{78,32,95}, Hewitt, John^{57,59}, Copeland, William E.⁹⁶, Middeldorp, Christel 28 M.44,45,46,50,51,97,47, Williams, Gail M.52, Wray, Naomi^{71,98}, Järvelin, Marjo-Riitta^{26,27,99}, McGue, 29 Matt²⁵, Iacono, William²⁵, Caspi, Avshalom^{59,100,88,101}, Moffitt, Terrie E.^{59,100,88,101}, Whitehouse, 30 Andrew¹⁰², Pennell, Craig E.^{23,24}, Klump, Kelly L.²², Jiang, Chang⁷⁰, Dick, Danielle M.^{103,104,78,105}, 31 Reichborn-Kjennerud, Ted77,106, Martin, Nicholas G.17, Medland, Sarah E.17,50,107, Vrijkotte, 32 Tanja^{108,46,109}, Kaprio, Jaakko^{110,14}, Tiemeier, Henning^{13,111}, Davey Smith, George^{112,10}, Hartman, 33 Catharina A.¹¹³, Oldehinkel, Albertine J.¹¹⁴, Casas, Miquel^{42,43,114,115}, Ribasés, Marta^{6,7,8}, 34 Lichtenstein, Paul⁵, Lundström, Sebastian^{116,117}, Plomin, Robert⁴, Bartels, Meike^{1,46}, Nivard, 35 Michel G.¹, Boomsma, Dorret I.^{1,46} 36

37		
38	1	Department of Biological Psychology, Vrije Universiteit Amsterdam, Amsterdam, The
39		Netherlands
40	2	Netherlands Institute for the Study of Crime and Law Enforcement
41	3	Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research,
42		Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
43	4	Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom
44	5	Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
45	6	Biomedical Network Research Centre on Mental Health (CIBERSAM), Instituto de Salud Carlos
46		III, Barcelona, Spain
47	7	Department of Mental Health, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
48	8	Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addiction, Vall d'Hebron
49		Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, Spain
50	9	Department of Epidemiology, University of Groningen, University Medical Center Groningen,
51		Groningen, The Netherlands
52	10	MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
53	11	Max Planck Institute for Psycholinguistics, The Netherlands
54	12	Donders Institute for Brain, Cognition and Behaviour, Radboud University, The Netherlands
55	13	Department of Child and Adolescent Psychiatry/Psychology, Erasmus University Medical Center,
56		Rotterdam, Netherlands
57	14	Institute for Molecular Medicine FIMM, HiLife, University of Helsinki, Helsinki, Finland
58	15	Department of Public Health, Amsterdam Public Health Research Institute, Amsterdam UMC,
59		location Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
60	16	Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam Public Health
61		Research Institute, Amsterdam UMC, location Academic Medical Center, University of
62		Amsterdam, Amsterdam, The Netherlands
63	17	QIMR Berghofer Medical Research Institute, Brisbane, Australia
64	18	K.G. Jebsen Centre for Neuropsychiatric Disorders, Department of Biomedicine, University of
65		Bergen, Norway
66	19	Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General
67		Hospital and Harvard Medical School, Boston, Massachusetts, USA
68	20	Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge,
69		Massachusetts, USA
70	21	Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, U.S.A
71	22	Department of Psychology, Michigan State University, East Lansing, USA
72	23	School of Medicine and Public Health. Faculty of Medicine and Health, The University of
73		Newcastle, Newcastle, New South Wales, Australia
74	24	Hunter Medical Research Institute, Newcastle, New South Wales, Australia
75	25	Department of Psychology, University of Minnesota, USA
76	26	MRC Centre for Environment and Health, Department of Epidemiology and Biostatistics, School
77		of Public Health, Imperial College London, London, United Kingdom
78	27	Faculty of Medicine, University of Oulu, PO Box 8000, FI-90014 Oulun yliopisto, Finland
79	28	Department of Sociology, College of Social and Behavioral Science, University of Utah
80	29	Department of Psychiatry, School of Medicine, University of Utah

81	30	Departments of Neurology and Computer Science, University of California Los Angeles,
82	21	California, USA
83	51	Department of Psychiatry and Behavioral Sciences, State University of New York Downstate
84	32	Health Sciences University, Brooklyn, NY, USA
85	52	Department of Psychiatry, Virginia Institute for Psychiatric and Behavioral Genetics, Virginia
86	33	Commonwealth University, Richmond, VA, USA
8/	34	Center for Genomic and Computational Biology, Duke University, Durham, NC, USA
88	54	Institute of Epidemiology, Helmholtz Zentrum München - German Research Center for
89	35	Environmental Health, Neuherberg, Germany
90 01		Ludwig-Maximilians-University of Munich, Dr. von Hauner Children's Hospital, Division of Matchelie Diseases and Natritional Madicine, Munich, Company
91	36	Developed Diseases and Nutritional Medicine, Munich, Germany
92	37	BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation (FPM), Barcelona, Spain
93	5,	Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology,
94	38	Barcelona, Spain
95	39	IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
90 07	40	CODE A.C. Consultance Descention Station on Arthurs in Childhard Hadresen I Conte for
9/		COPSAC, Copennagen Prospective Studies on Astrima in Childhood, Herley and Gentone
98	41	Hospital, University of Copenhagen, Copenhagen, Denmark
99 100	42	Steno Diabetes Center Copennagen, Herley, Denmark
100		SJD MIND Schools Program, Hospital Sant Joan de Deu, Institut de Recerca Sant Joan de Deu,
101	43	Esplugues de Llobregat, Spain
102		Department of Psychiatry and Legal Medicine, Universität Autonoma de Barcelona, Barcelona,
103	44	Spain Department of shild and adalassent resultistry and resultates. A metandam UMC A metandam
104	45	Department of child and adorescent psychiatry and psychology, Amsterdam UNC, Amsterdam
105	46	Amstender Dublic Health Descende Institute, Amsterdam, the Netherlands
100	47	Amsterdam Public Healin Research Institute, Amsterdam, the Netherlands
107	48	Deportment of Clinical Educational and Health Brychology, University College London
100		London LIK
110	49	Montal Health and Neuroscience Desearch Program OIMP Perghafer Medical Desearch Institute
110		Prishana Australia
117	50	School of Psychology University of Oueensland Brishane Australia
112	51	Center for Innovation in Public Health University of Kentucky
114	52	School of Public Health The University of Queensland Herston Old Australia
115	53	Child Health Research Centre. The University of Queensland, Herston, Qid, Australia
116	54	Child and Vouth Mental Health Service. Children's Health Oueensland Hospital and Health
117		Service Brisbane OLD Australia
118	55	Oueensland Centre for Mental Health Research OLD Australia
110	56	Institute for Behavioral Genetics, University of Colorado Boulder, Colorado, USA
120	57	Department of Ecology and Evolutionary Biology University of Colorado Boulder, Colorado
120		USA
121	58	Department of Psychology and Neuroscience Duke University Durham N.C. U.S.A
122	59	Avera Institute for Human Genetics, Sioux Falls, South Dakota, USA
140		Avera instance for Human Genetics, Sloux I ans, South Dakota, USA

124	60	Translational Neurogenomics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane,
125		Queensland, Australia
126	61	School of Medical Sciences, Orebro University, Orebro, Sweden
127	62	Department of Biomedical Data Sciences, Molecular Epidemiology, Leiden University Medical
128		Center, Leiden, The Netherlands
129	63	Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands
130	64	Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA
131	65	Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The
132		Netherlands
133	66	Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging
134		(NCHA), Leiden, The Netherlands
135	67	Centre for Fertility and Health, The Norwegian Institute of Public Health, Oslo, Norway
136	68	Department of Genetics and Bioinformatics, Division of Health Data and Digitalization,
137		The Norwegian Institute of Public Health, Bergen, Norway
138	69	Department of Clinical Science, University of Bergen, Norway
130	70	Department of Biostatistics University of Florida Gainesville USA
140	71	Institute for Molecular Bioscience University of Queensland OLD Australia
140	72	Institute for Notecular Dioscience, Oniversity of Queensland, QLD, Australia
141	73	Department of Psychiatry University of California San Diego
142	74	University of Colorado School of Medicine, Aurora, Colorado, USA
143	75	Department of Molecular Cellular and Developmental Biology University of Colorado Boulder
145		USA
146	76	Department of Psychology University of California Riverside Riverside CA USA
147	77	Department of Psychology and Neuroscience University of Colorado Boulder, Colorado USA
148	78	Department of Human and Molecular Genetics. Virginia Commonwealth University, Richmond
149		VA USA
150	79	Department of Pathology and Biomedical Science, and Carney Centre for Pharmacogenomics
151		University of Otago Christchurch New Zealand
152	80	PsychGen Centre for Genetic Enidemiology and Mental Health Norwegian Institute of Public
153		Health Oslo Norway
154	81	Nic Waals Institute, Lovisenberg Diaconal Hospital, Oslo, Norway
155	82	Epidemiology and Environmental Health Joint Research Unit, FISABIO-Universitat Jaume I-
156		Universitat de València, Valencia (Spain)
157	83	Spanish Consortium for Research on Epidemiology and Public Health (CIBERESP), Madrid
158		(Spain)
159	84	Department of Nursing, Universitat de València, Valencia, Spain
160	85	ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain
161	86	Universitat Pompeu Fabra (UPF), Barcelona, Spain
162	87	CIBER Epidemiología y Salud Pública (CIBERESP), Spain
163	88	Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and
164		Neuroscience, King's College London, U.K.
165	89	Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine. University
166		of Munich Medical Center, Ludwig-Maximilians-Universität München, Munich, Germany
		, <u> </u>

167	90	Allergy and Lung Health Unit, Melbourne School of Population and Global Health, University of
168		Melbourne, Melbourne, Australia
169	91	Christchurch Health and Development Study, Department of Psychological Medicine, University
170		of Otago Christchurch, New Zealand
171	92	Biostatistics and Computational Biology Unit, Department of Pathology and Biomedical Science,
172		University of Otago Christchurch, New Zealand
173	93	Department of Pathology and Biomedical Science, and Carney Centre for Pharmacogenomics,
174		University of Otago Christchurch, New Zealand
175	94	Dunedin Multidisciplinary Health and Development Research Unit, University of Otago,
176		Dunedin, New Zealand
177	95	Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA
178	96	Department of Psychiatry, College of Medicine, University of Vermont
179	97	Arkin mental health care, Amsterdam, The Netherlands
180	98	Queensland Brain Institute, Institute for Molecular Bioscience, University of Queensland, St
181		Lucia 4072, Australia
182	99	Department of Life Sciences, College of Health and Life Sciences, Brunel University London,
183		London, United Kingdom
184	100	Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine,
185		Durham, N.C., U.S.A.
186	101	Center for Genomic and Computational Biology, Duke University, Durham, N.C., U.S.A.
187	102	Telethon Kids Institute, University of Western Australia, Nedlands, Western Australia, Australia
188	103	Department of Psychiatry, Robert Wood Johnson Medical School, Rutgers University, U.S.A.
189	104	Department of Psychology, Virginia Commonwealth University, U.S.A.
190	105	College Behavioral and Emotional Health Institute, Virginia Commonwealth University,
191		Richmond, VA, USA
192	106	Institute of Clinical Medicine, University of Oslo, Oslo, Norway
193	107	School of Psychology and Counselling, Queensland University of Technology, Brisbane,
194		Australia
195	108	Department of Public and Occupational Health, Amsterdam University Medical Center,
196		University of Amsterdam, Amsterdam
197	109	Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands
198	110	Department of Public Health, Medical Faculty, University of Helsinki, Helsinki, Finland
199	111	Department of Social and Behavioral Science, Harvard TH Chan School of Public Health, Boston,
200		USA
201	112	Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
202	113	Interdisciplinary Center Psychopathology and Emotion regulation (ICPE), Department of
203		Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The
204		Netherlands
205	114	Fundació d'Investigació Sant Pau, Barcelona, Spain
206	115	Instituto para el Desarrollo de Terapias Avanzadas en Neurociencias (IDETAN). Barcelona, Spain
207	116	Gillberg Neuropsychiatry Centre, University of Gothenburg, Gothenburg, Sweden
208	117	Centre for Ethics, Law and Mental Health, University of Gothenburg, Gothenburg, Sweden
209		

210 Abstract

211 Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder for 212 which genetic factors explain up to 75% of the variance. In this study, we performed a genome-213 wide association meta-analysis (GWAMA) of ADHD symptom measures, with an effective sample 214 size of 120,092 (71,733 unique individuals from 28 population-based cohorts, with 288,887 215 quantitative ADHD symptom measures). Next, we meta-analyzed the results with a genome-wide 216 association study (GWAS) of ADHD diagnosis. The GWAMA of ADHD symptoms returned no 217 genome-wide significant variants. However, we estimated strong genetic correlations between our study of quantitative ADHD symptoms and the earlier study of ADHD diagnosis (r_g = 1.00, SE= 218 0.06). Moderate negative genetic correlations ($r_g < -0.40$) were observed with several cognitive 219 220 traits. Genetic correlations between ADHD and aggressive behavior and antisocial behavior were 221 around 1. This provides further evidence of the wide pleiotropic effects of genetic variants and the 222 role that genetic variants play in the co-occurrence with (mental) health traits. The GWAMAs of 223 ADHD symptoms and diagnosis identified 2,039 genome-wide significant variants, representing 224 39 independent loci, of which 17 were new. Using a novel fine-mapping and functional annotation 225 method, we identified 22 potential effector genes which implicate several new potential biological 226 processes and pathways that may play a role in ADHD. Our findings support the notion that clinical 227 ADHD is at the extreme end of a continuous liability that is indexed by ADHD symptoms. We 228 show that including ADHD symptom counts in large-scale GWAS can be useful to identify novel 229 genes implicated in ADHD and related symptoms.

230

²³¹ Keywords: ADHD, GWAS, symptoms, diagnosis, genetics, FLAMES

233 Introduction

234 Attention-deficit/hyperactivity disorder (ADHD) is, for many individuals, a persistent 235 neurodevelopmental disorder (Faraone et al., 2006; Kan et al., 2013). ADHD is characterized by 236 three core symptoms: hyperactivity, impulsivity, and inattention (American Psychiatric 237 Association, 2013). It affects around 5% of children and adolescents and 2.5% of adults worldwide 238 (Faraone et al., 2015). ADHD may be associated with serious consequences for affected 239 individuals, their families, and society at large, with symptoms persisting across multiple settings, 240 i.e. at home, at school, and elsewhere (Caci et al., 2014, 2015). The disorder has a predominantly 241 genetic aetiology, involving both common and rare genetic variants (Faraone et al., 2024). The 242 mean estimated heritability across 37 twin studies of ADHD was 74% (Faraone & Larsson, 2019; 243 Kan et al., 2014; Merwood et al., 2013), with some differences in heritability across ages and raters 244 (Kan et al., 2014; Merwood et al., 2013).

245 In 2019, a genome-wide association meta-analysis (GWAMA) of clinical ADHD, hereafter 246 referred to as ADHD_{DIAG2019}, including data from 20,183 cases and 35,191 controls, identified the 247 first 12 genome-wide significant loci associated with ADHD (Demontis et al., 2019). The study 248 reported that 22% of the variance in ADHD could be explained by all measured single nucleotide 249 polymorphisms (SNPs). They also performed meta-analyses with deCode, 23andMe, and EAGLE 250 (Middeldorp et al., 2016). Four independent loci reached the genome-wide significance threshold 251 $(p \le 5 \times 10^{-8})$ in all three meta-analyses. Interestingly, most independent significant loci, 15, were 252 found in the meta-analysis with a quantitative assessment of attention problems in EAGLE, 253 suggesting that quantitative assessments of ADHD can boost the power to identify implicated 254 genetic variants. Ten independent significant loci were found in meta-analyses with deCode and 255 23andMe data. In 2023, Demontis and colleagues presented results from their updated GWAS

256 meta-analysis of ADHD (ADHD_{DIAG}), combining newly extended data from iPSYCH, deCode, 257 and the PGC, almost doubling the number of cases compared with ADHD_{DIAG2019} (Demontis et al., 258 2023). The definition of cases was broader, for example by including individuals who used ADHD 259 prescription medication. The study reported 27 independent significant loci and estimated that 14% 260 of the variance in ADHD could be attributed to the included SNPs. The broader definition of 261 ADHD diagnosis resulted in a larger sample and, therefore, more power to detect implicated 262 genetic variants. However, this broader definition also increased the heterogeneity of the 263 phenotype, which may explain the decrease in SNP-heritability (Wang et al., 2023).

264 There is increasing interest and recognition that ADHD symptom counts in non-clinical 265 samples can tap into the same genetic construct as clinically diagnosed ADHD, supporting the 266 notion that 'clinical ADHD' is at the extreme end of a continuous measure of ADHD symptoms 267 (Larsson et al., 2012; Levy et al., 1997). This was initially suggested based on multivariate twin 268 studies (Derks et al., 2008). Additionally, the genetic correlation (r_a) between quantitative ADHD 269 symptom counts (Middeldorp et al., 2016) and ADHD_{DIAG2019} (Demontis et al., 2019) was estimated to be 0.97 (SE= 0.21, $p= 2.66 \times 10^{-6}$), suggesting that combining these measures is a 270 271 viable strategy to increase statistical power in ADHD GWASs. This was additionally supported by 272 the increased number of genome-wide significant loci in the meta-analysis of ADHD_{DIAG2019} and 273 EAGLE, as compared to ADHD_{DIAG2019} alone, and to meta-analyses of ADHD_{DIAG2019}, deCode and 274 23andMe.

In this study, we combine information from 28 population-based cohorts in a GWAMA of continuous ADHD symptom scores, leading to a total of 71,733 participants. The measures include repeated assessments (longitudinal data) by multiple raters (maternal, paternal, teachers, and selfassessments) and instruments across ages (range: 2-18 years), for a total of 288,887 measures. We

279 also include retrospective self-report data. We meta-analyze all available data into a crossrater/cross-age/cross-instrument GWAMA of ADHD symptoms (ADHD_{symp}), taking into 280 281 consideration the dependency between multiple assessments within individuals (Ip et al., 2021). 282 Using measures from multiple raters and ages may further increase the power of the analyses due 283 to an increase in the validity of the ADHD symptom measures. Next, we estimate the genetic correlations (r_g) between ADHD_{SYMP} and the meta-analysis of case-control samples (Demontis et 284 285 al., 2023), and meta-analyze ADHD_{SYMP} with ADHD_{DIAG} (ADHD_{overall}). Finally, we performed 286 fine mapping and gene-based tests based on ADHD_{SYMP} and ADHD_{overall}, performed several 287 follow-up enrichment and pathway analyses, and estimated genetic correlations between the 288 GWAMA and a set of predefined outcomes from cognitive and externalizing behaviour domains.

289

290

291 **Results**

ADHD_{SYMP} **GWAMA**

We first meta-analyzed the effect of each SNP across all available univariate GWAS of quantitative ADHD measures. Based on an effective sample size of 120,092, the estimated h_{SNP}^2 of ADHD_{SYMP} was 0.04 (SE= 0.01; Z= 8.12). The mean χ^2 statistic was 1.09 along with an LDSC-intercept of 1.01 (SE= 0.01), indicating that there was no or very limited inflation in test statistics due to confounding biases such as population stratification. Rather, the GWAMA most likely captured the polygenic nature of childhood ADHD symptoms. The GWAMA of ADHD symptoms did not result in any genome-wide significant SNPs (Figure 1, Supplements Table 11).



- 301 Figure 1. Manhattan plot: GWAMA of ADHD symptoms.
- 302

300

303 Meta-analysis with ADHD diagnosis GWAS

SNP-heritability estimated with genomicSEM was 0.13 (SE= 0.01) for ADHD_{DIAG}. The estimated genetic correlation between ADHD_{SYMP} and ADHD_{DIAG} was 1.00 (SE= 0.06). The CTI was not significantly different from zero and were subsequently constrained to zero in the following metaanalysis.

308 Because the point estimate of the genetic correlation between ADHD_{SYMP} and ADHD_{DIAG} 309 was not significantly different from 1, we constrained the genetic correlation at unity when pre-310 adjusting the weights and Z-scores for the meta-analysis of ADHD_{SYMP} and ADHD_{DIAG}. A total of 311 6,571,852 SNPs were included in the meta-analysis. The SNP-heritability of ADHD_{overall} was 0.11 312 (SE= 0.01), with a mean χ^2 statistic of 1.52. The LDSC-intercept and ratio were 1.02 (SE= 0.01) 313 and 0.03 (SE= 0.02), respectively, indicating that approximately 3% of the signal might be due to 314 confounding factors. A Manhattan plot of ADHD_{overall} is shown in Figure 2. 2,039 SNPs reached 315 genome-wide significance ($p < 5 \ge 10^{-8}$), of which 644 were also reported in ADHD_{DIAG} and 1,395 10

- 316 were new. The 2,039 SNPs corresponded to 43 independent lead SNPs in 39 independent
- 317 significant loci, identified with FUMA. Of these 39 loci, 22 were also reported in ADHD_{DIAG} and
- 318 17 were new. See also Figure 2 and Supplements Tables 12 and 13.



Figure 2. Manhattan plot: GWAMA of ADHD symptoms and ADHD diagnosis. *Note: orange dots reflect lead SNPs.*

- 322
- 323

324 Follow-up analyses

- 325 *Fine mapping & gene-based tests*
- 326 Gene mapping in FUMA mapped the 43 lead SNPS in 39 independent genomic risk loci to 204
- 327 associated genes (See Supplements Table 14), of which 45 were also reported by Demontis et al
- 328 (2023). Second, gene-based tests were run in MAGMA (de Leeuw et al., 2015), identifying 64
- 329 associated genes (see Supplements Table 15), of which 17 were previously reported by Demontis
- et al. (2023). Third, we ran FLAMES (Schipper et al., 2023), with the aim to get a better
- understanding of the genes that are causally involved in ADHD. A total of 22 genes had

332 FLAMES scores larger than 0.05, and were interpreted as potential effector genes (see

333 Supplements Table 16). Fourteen of these effector genes were also tagged by the MAGMA gene-

based test. Ten of these potential effector genes were previously reported by Demontis et al.

335 (2023). Four genes were not reported by Demontis et al. (2023) but have previously been linked

to ADHD, as listed by GWAS Catalog. Eight potential effector genes were not reported by

337 Demontis et al. (2023) or by any ADHD specific studies listed on GWAS Catalog: *EMCN*,

338 *STK32C*, *PCDH17*, *TCF12*, *PEAK1*, *IGF1R*, *CTNNA2*, and *ABCA12*.

339

340 Enrichment & tissue specific expression

Gene-set analysis in MAGMA revealed no significant enrichment in any MSigDB v2023 gene-sets after correction for multiple testing. MAGMA expression analysis showed significant enrichment of the GWAMA signal in gene-sets differentially expressed in late infancy. Additionally, there was significant enrichment in several brain tissue types, as well as in the pituitary gland (See Supplements Figures 1 and 2).

346 Next, FUMA GENE2FUNC gene-set enrichment analyses of the 204 potential ADHD risk 347 genes mapped by FUMA showed significant enrichment in genes identified in GWAS of ADHD, 348 cognition-related phenotypes, and risk-taking behaviors. The genes were not significantly enriched 349 in any tissue types, or in any of the Brainspan developmental stages of brain samples. Genes were 350 enriched in 29 gene sets that code for transcription factor targets. Zero synpase cellular component 351 terms or biological processes were significantly enriched at 1% FDR (testing terms with at least 352 three matching input genes in SynGO). For a complete overview of all enrichment results and the 353 included gene sets, see Supplemental Figures 3-5, and Supplemental Notes.

We repeated the same analyses for the 22 potential effector genes identified by FLAMES.Again, genes were highly enriched for genes identified in GWAS of cognition-related phenotypes,

356 and risk-taking behaviors. The 22 genes were significantly overrepresented in gene sets that are 357 differentially expressed in the frontal cortex, but not in the "general tissue" type brain, or in any of 358 the Brainspan developmental stages. Genes were also enriched in 52 gene sets that code for 359 transcription factor targets, 13 microRNA targets, 4 gene ontology biological processes, 1 360 canonical pathway, and 8 cell type signatures. Zero synpase cellular component terms or biological 361 processes were significantly enriched at 1% FDR (testing terms with at least three matching input 362 genes in SynGO). Nine genes were mapped to SynGO annotations, eight to cellular components 363 and 9 to biological processes. Genes were enriched in integral components of the postsynaptic density membrane ($q= 1.46 \times 10^{-3}$), postsynaptic density ($q= 1.57 \times 10^{-3}$), postsynapse (q=364 5.67 \times 10⁻³), and synapse ($q = 7.22 \times 10^{-3}$), as well as in postsynaptic modulation of chemical 365 synaptic transmission ($q = 3.28 \times 10^{-5}$), process in the synapse ($q = 3.97 \times 10^{-4}$), and synapse 366 organization ($q = 1.62 \times 10^{-3}$). For a complete overview of all enrichment results and the included 367 368 gene sets, see Supplemental Figures 6-12, Supplementary Tables 17 and 18, and Supplemental 369 Notes.

370

371 *Genetic correlations*

We estimated genetic correlations between ADHD_{overall} and 49 external phenotypes. Results are shown in Figure 4 and Supplementary Table 18. Strong positive genetic correlations were observed between ADHD_{overall} and childhood aggressive behavior (r_g = 1.13, SE= 0.05) and antisocial behavior (r_g = 0.97, SE= 0.06). The correlation of 1.13 with childhood aggressive behavior reflects a high genetic correlation that is likely greater than 1 due to sampling variation, correlations estimated by LD score regression in genomicSEM are not bounded between -1 and 1 (Childhood aggression $h^2 Z$ = 9.03). Measures of smoking habits (r_g = 0.46-0.6, SE= 0.03) and number of

379 children ($r_g = 0.38$, SE= 0.04) also showed moderate correlations, as did ratings of overall health $(r_g = -0.59, SE = 0.03)$, educational attainment $(r_g = -0.55, SE = 0.02)$, and childhood IQ $(r_g = -0.43, SE = 0.02)$ 380 381 SE= 0.06). In general, ADHD_{overall} showed weak to moderate genetic correlations with psychopathologies, including Major Depressive Disorder ($r_g = 0.57$, SE= 0.03) and Autism 382 Spectrum Disorder ($r_g = 0.39$, SE= 0.04). Weak negative genetic correlations were found between 383 ADHD_{overall} and alcohol intake frequency ($r_q = -0.28$, SE= 0.03), but a weak positive correlation 384 with drinks per week ($r_g = 0.14$, SE= 0.03) and a weak positive correlation with cannabis use ($r_g =$ 385 0.2, SE= 0.03). Marees and colleagues (Marees et al., 2020) looked into similar genetic correlations 386 387 for alcohol use, and found evidence to suggest that they are the result of SES influences. ADHD_{overall} was weakly negatively genetically correlated with birth weight ($r_g = -0.1$, SE= 0.02), 388 389 but showed a weak positive genetic correlation with childhood obesity ($r_q = 0.21$, SE=0.05) and a 390 moderate positive genetic correlation with adult BMI ($r_q = 0.3$, SE= 0.02).





Discussion

396 We present a genome-wide association meta-analysis of childhood Attention-Deficit/Hyperactivity

397 Disorder symptoms (ADHD_{SYMP}). A total of 28 cohorts with measures of ADHD symptom counts

took part; contributing data from multiple raters and instruments, across a wide range of ages. We
meta-analyzed all continuous measures and combined these results with results from two
GWAMAs of ADHD diagnosis (ADHD_{DIAG}) by Demontis and colleagues (2019, 2023).

401 We did not identify any genome-wide significant hits for ADHD symptoms specifically. 402 Genetic correlations with ADHD diagnosis was $r_g = 1.00$, SE= 0.06. This supports the notion that 403 clinical ADHD is at the extreme end of a continuous genetic liability that is indexed by ADHD 404 symptoms (Larsson et al., 2012; Levy et al., 1997). This was previously suggested based on multivariate twin studies (Derks et al., 2008). The estimated h_{SNP}^2 of ADHD_{SYMP} was 0.04 (SE= 405 0.01), which may be considered low compared to the estimated h_{SNP}^2 in Demontis et al., 2019 and 406 407 2023: 0.22 and 0.14 respectively. This is probably because we introduced heterogeneous 408 measurement error and bias in our phenotyping by including symptom measures from different 409 raters, and at different ages, which could subsequently suppress SNP-heritability.

410 By meta-analyzing GWASs of ADHD symptoms and ADHD diagnosis, we found 2,039 411 genome-wide significant variants in 39 independent loci, of which 17 were new. Demontis et al. 412 found 12 and 27 independent hits in 2019 and 2023, which included data from 23andMe. These 413 23andMe data were excluded from the current meta-analyses. This shows that, because ADHD 414 symptom measures have been widely collected, combining ADHD symptom counts and diagnosis can be effective in identifying implicated genetic variants for ADHD. The estimated h_{SNP}^2 of 415 416 ADHD_{overall} was 0.11 (SE= 0.01), compared to 0.13 (SE= 0.01) in ADHD_{DIAG} when excluding 23andMe data. This means that by including ADHD_{SYMP} in the ADHD_{DIAG} results, h_{SNP}^2 slightly 417 decreased. We believe this is due to heterogeneous measurement error and bias in the ADHD_{SYMP} 418 419 phenotyping (Wang et al., 2023). The same can be observed when looking at the differences in h_{SNP}^2 between ADHD_{DIAG} from 2019 ($h_{SNP}^2 = 0.22$, including 23andMe), which was strict in its 420

421 definition of ADHD cases, and ADHD_{DIAG} from 2023 ($h_{SNP}^2 = 0.14$, including 23andMe), which 422 was slightly more lenient in its definition of ADHD cases.

423 MAGMA analyses identified 64 potential ADHD risk genes. These genes were 424 significantly enriched in genes previously identified in GWASs of cognitive phenotypes and risk-425 taking behaviors. The total GWAS signal was significantly differentially expressed in several brain 426 specific tissue types, general brain tissue types and the pituitary gland, as well as in late infancy 427 Brainspan brain samples. FUMA gene-mapping mapped significant loci to 204 genes. Again, genes 428 were enriched in gene-sets reported by previous GWASs on cognitive behavior, risk-seeking 429 behavior, and brain development. FUMA enrichment analyses further revealed 29 transcription 430 factor targets that may be of interest for ADHD.

431 To get a better understanding of the causal pathways from SNPs to ADHD, we ran 432 FLAMES (Schipper et al., 2023) to identify likely effector genes. FLAMES identified 22 potential 433 effector genes, of which 14 overlapped with the MAGMA genes, 12 were previously reported by 434 Demontis et al. (2023) and 8 were not previously linked to ADHD or not reported on GWAS 435 Catalog. The 22 genes were significantly overrepresented in gene-sets differentially expressed in 436 the frontal cortex, enriched in 4 GO biological processes related to neural and physical 437 development, 52 transcription factor targets, 13 microRNA targets, 8 different cell type signatures, 438 4 synapse cellular components, and 3 synaptic biological processes. In Demontis et al. (2023), the 439 set of potential ADHD risk genes was significantly enriched among genes upregulated during early 440 embryonic brain development, this result was not replicated in our study. A common theme is that 441 implicated genes are enriched in processes that are involved in neural development and functioning. 442 The results provide several new avenues to investigate, which could prove useful in gaining more 443 insights into the etiology of ADHD. The results may provide more potentially useful information 444 for the 22 potential effector genes compared to the 204 genes identified by FUMA positional

445 mapping, eQTL mapping, and chromatin interaction mapping. We think this difference results from 446 the difference in strategies employed by both methods. FUMA maps every gene for which some 447 functional link is known to exist, whereas FLAMES weighs all these measurements and only 448 prioritizes genes if they are clearly more likely causal genes than the other genes in the locus. Our 449 findings suggests that FLAMES can help identify functional pathways that may remain hidden 450 with other approaches due to a reduction of noise from non-causal genes in the set of prioritized 451 genes, which decreases the power to detect enrichment in functional gene-sets.

452 Next, we examined genetic correlations between ADHD_{overall} and various external 453 phenotypes. Except for anorexia nervosa, ADHD_{overall} showed significant genetic correlations with 454 all examined psychopathological traits. Most striking was the genetic correlation of 1.13 with 455 childhood aggressive behavior, and 0.97 with antisocial behavior. Previous studies reported 456 moderate-to-strong phenotypic correlations across sex-, rater-, age-, and instrument-specific 457 assessment between aggressive behavior and attention problems and hyperactivity (Bartels et al., 458 2018). We found a negative genetic correlation between ADHD and alchohol intake frequency, 459 and a positive correlation between ADHD and number of drinks per week. Marees et al. (2020) 460 studied similar correlations between alcohol consumption and mental health traits, and found 461 evidence that suggests the different genetic correlations are a result of SES effects. We found a 462 moderate genetic correlation with smoking behaviors, but a small correlation with cannabis use 463 and discrepant findings for alcohol consumption. This was surprising, given the phenotypic 464 associations that have been reported in previous studies (Lee et al., 2011). We found negative 465 correlations with several cognitive traits, such as (childhood) IQ, verbal-numerical reasoning, and 466 educational attainment. Similar to a GWAS of childhood aggression (Ip et al., 2021), genetic 467 correlations with several hormone levels were around zero. Finally, we found a small negative 468 correlation with birthweight, but a weak positive correlation with childhood obesity, and adult

BMI. These genetic correlations suggest wide pleiotropic effects of variants involved with ADHD. This is illustrative of the polygenetic nature of most behavioral, cognitive, and (mental) health traits. It also indicates genetic factors play a role in the comorbidity of psychopathological disorders.

473 Combining data collected using different instruments and by different raters helps to increase the sample size, and with that the statistical power of our analyses. This is illustrated by 474 475 the apparent increase in power to detect genetic variants associated with ADHD in the combination 476 ADHD_{SYMP} and ADHD_{DIAG}, compared to the combination ADHD_{DIAG} and EAGLE ADHD GWAS 477 (Demontis et al., 2019; Middeldorp et al., 2016). However, this approach of including different 478 raters and instruments also has some downsides. Correlations between raters and instruments are 479 not always large, meaning that we introduce heterogeneous measurement error and bias in our 480 phenotyping, which could suppress SNP-heritability. More homogeneous measurement may offer 481 an avenue to higher powered GWAS. In light of increased collaborations between cohorts to 482 expand sample sizes for GWAS, more efforts to standardize the assessment of traits could help 483 further increase the power and specificity of GWAS results. Moreover, downstream analyses, for 484 example using polygenic scores computed with the summary statistics of the current study, will 485 favor cohorts using the same instruments and raters that dominated the discovery sample, in our 486 case the Achenbach System of Empirically Based Assessment (Achenbach et al., 2017).

Assessments of ADHD in individuals from non-European ancestry were rare in each of the included cohorts. Because of the low number of assessments, we were forced to exclude non-European individuals from our analyses. We know that results from European ancestry GWASs often also significantly predict differences in non-European ethnic groups, but often effect sizes are diluted towards zero. Regrettably, this means that knowledge generated by these types of studies risks benefit individuals of European ancestry more than from diverse backgrounds. To

493 better understand the etiology of ADHD across individuals and backgrounds, it is important to494 continue ongoing efforts to increase the inclusivity of GWAS samples.

495 In conclusion, the current study adds novel insight into the genetic etiology of ADHD. By 496 meta-analyzing GWAS results from symptom counts of ADHD in children with a diagnosis of 497 ADHD, we identified novel genome-wide significant loci and genes. The number of genome-wide 498 (significant) genetic variants that are implicated in ADHD provides further insight into the 499 polygenic etiology of ADHD. The 22 potential effector genes that were identified by FLAMES 500 gives insight in several biological processes that may play a causal role in the etiology of ADHD, 501 and provides avenues for further research. The genetic correlations with other phenotypes further 502 indicate the wide pleiotropic effects of genetic variants and the role that genetic variants play in 503 the co-occurrence with (mental) health traits.

504

505

506 <u>Methods</u>

507 Sample & cohorts

508 Childhood cohorts that collaborate within the ACTION (Aggression in Children: unraveling gene-509 environment interplay to inform Treatment and InterventiON strategies) consortium (Bartels et al., 510 2018; Boomsma, 2015; Ip et al., 2021) and EAGLE consortium (Middeldorp et al., 2019) took part 511 in the meta-analysis of ADHD symptom counts (ADHD_{SYMP}). Cohorts assessed ADHD Symptoms 512 in children and adolescents aged 1.5 to 18 years and also included adult retrospective assessments. 513 Each cohort received standard operation protocol https://www.actionа (see: 514 euproject.eu/content/data-protocols). Cohorts could contribute one or several univariate genome-515 wide association studies (GWAS). A separate analysis was performed for every unique

combination of rater, instrument, and age, with a minimum of 450 observations per GWAS (so that each GWAS included a maximum of one measure for each individual). Extended information on the cohorts can be found in Supplementary Table 1 and the Supplementary Text. Assessments of individuals of non-European ancestry were limited, and analyses were restricted to individuals of European ancestry. In total, 28 cohorts contributed 154 GWASs, resulting in a total of 288,887 observations from 72,483 unique individuals (Supplementary Table 2).

522

523 Measurement of ADHD symptoms

524 ADHD symptoms in children and adolescents were rated by parents, teachers, and the individuals 525 themselves. Additionally, retrospective assessments of (pre-) adolescent ADHD symptoms from 526 self-report or maternal report were included in the GWAMA. To maximize sample size, we 527 included measurement of ADHD symptoms across multiple instruments. In total, 22 ADHD 528 symptom assessment instruments were included in the meta-analysis (Supplementary Table 3). The 529 most commonly employed instruments were the Achenbach System of Empirically Based 530 Assessment (Achenbach et al., 2017) and the Strengths and Difficulties Questionnaire (Goodman, 531 2001).

532

533 Genotyping and quality control

Genotyping was performed within each cohort using common genotyping arrays (see Supplementary Table 4), followed by cohort-specific quality control based on individual- and variant-based call rate, Hardy-Weinberg equilibrium, excessive heterozygosity rates, and minor allele frequency (see Supplementary Table 5). Cohorts removed samples with non-European ancestry. 78.6% of the cohorts imputed their genotypes to 1000 Genomes (1000G) phase 3 version 5, while the remaining cohorts used 1000G phase 1 version 3 as the reference set for the imputation

(Supplementary Table 6). All genotypes were mapped to build 37 of the Human Genome ReferenceConsortium assembly (GRCh37).

542

543 GWA model

Each cohort performed a univariate GWAS where ADHD symptoms were regressed on the SNP genotype, with age, sex, and first five ancestry-based principal components as fixed effects, and, if necessary, cohort-specific covariates (Supplementary Table 7). To correct for dependency between observations within univariate analyses, cohorts with related individuals applied a mixed linear model (Tucker et al., 2015) or a sandwich correction of the standard errors (Minică et al., 2015).

GWASs were stratified by (1) rater, (2) instrument, and (3) age, so that observations within a univariate GWAS were independent, with a minimum stratum sample size of 450 observations. In total, summary statistics for 154 univariate GWAS were uploaded. Descriptive statistics for each uploaded GWAS are shown in Supplementary Table 8. Each cohort also supplied information on the degree of sample overlap and phenotypic correlation between their univariate analyses. These statistics allowed us to account for dependency between observations within cohorts.

555

556 **Pre-GWAMA QC**

Summary statistics from each GWAS went through quality control (QC) using the EasyQC software package (Winkler et al., 2014). SNPs with a genotyping rate below 95% were removed. We applied variable QC filters on MAF and HWE *p*-value tailored to the sample size in the specific GWAS. Respective cutoffs of INFO> 0.6 and INFO> 0.7 were applied to SNPs that were imputed using MACH and IMPUTE (Liu et al., 2015). Reported allele frequencies were compared to the allele frequency in an imputation-matched reference population and variants with an absolute difference in allele frequency larger than 0.2 were removed. Supplementary Table 9 reports thenumber of SNPs before and after QC.

565

566 Meta-analysis of ADHD symptoms

567 The meta-analysis method is equal to the method described by Ip and colleagues (Ip et al., 2021). 568 Due to sample overlap between the univariate GWASs, covariance between GWAS test statistics 569 are a function of sample overlap and a truly shared genetic signal (Bulik-Sullivan, Loh, et al., 570 2015). To correct for sample overlap during the meta-analysis, we applied a modified version of 571 the multivariate meta-analysis approach developed by Baselmans and colleagues (2019), where we 572 calculated the expected cross-trait-intercept (Bulik-Sullivan, Loh, et al., 2015) based on the 573 observed sample overlap and phenotypic covariance, as reported by the cohorts. Finally, because 574 the sum of the number of observations (Nobs) was an overestimate of the effective sample size (N_{eff}), we approximated the effective sample size as proposed by Ip and colleagues (2021) (N_{eff} = 575

- 576 $\frac{4}{\left(\frac{1}{N_{cases}} + \frac{1}{N_{controls}}\right)}$). SNPs with MAF< 0.01, N_{eff}< 15,000, or were observed in only one cohort were
- 577 removed from further analyses. SNP-heritability (h_{SNP}^2) was estimated by genomic Structural 578 Equation Modeling in R (Grotzinger et al., 2019).
- 579

580 Meta-analysis with case-control ADHD GWAS

In the next step, we meta-analyzed our ADHD_{SYMP} GWAMA with a GWAS of ADHD diagnosis (Demontis et al., 2023). In ADHD_{DIAG}, cases are defined as clinically diagnosed with ADHD or prescribed medication specific for ADHD. ADHD_{DIAG} included data from the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), the Psychiatric Genomics

585 Consortium (PGC), and deCode. Data were obtained for adults and children, resulting in a total of
586 38,691 cases and 186,843 controls.

587 For the meta-analysis, we first adjusted the test statistics and sample sizes for ADHD_{SYMP} 588 and $ADHD_{DIAG}$ as proposed by (Demontis et al., 2019). The lifetime population prevalence of 589 ADHD was assumed to be 5% (Faraone et al., 2015). SNP-heritability for ADHD_{SYMP}, and ADHD_{DIAG}, and r_g and cross-trait intercepts (CTI) between ADHD_{SYMP} and ADHD_{DIAG} were 590 591 estimated by genomicSEM in R (Grotzinger et al., 2019). We meta-analyzed the results from 592 ADHD_{SYMP} and ADHD_{DIAG} based on the approach outlined in Baselmans and colleagues 593 (Baselmans et al., 2019). We specified the effective sample sizes for ADHD_{DIAG} as suggested by Ip and colleagues (2021): $N_{eff} = \frac{4}{\left(\frac{1}{N_{cases}} + \frac{1}{N_{controls}}\right)}$. SNP-heritability was estimated using LDSC in 594

genomicSEM (Grotzinger et al., 2019). We assumed no sample overlap between ADHD_{SYMP} and
 ADHD_{DIAG}.

597

598 **Follow-up analyses**

599 *Fine mapping & gene-based tests*

600 We used FUMA (Watanabe et al., 2017) to identify independent genome-wide significant loci 601 and associated genes. LD blocks of independent significant SNPs within 250kb were merged into 602 a single genomic locus. Protein-coding genes were mapped if they were located within a 603 maximum distance of 10 kb of an independent significant SNP, or if a credible variant was 604 annotated to the gene based on eQTL data or chromatin interaction data from human brain (see 605 Supplemental Text for the included datasets). These are the same settings used by Demontis et al. 606 (Demontis et al., 2023). Gene-based tests were run in MAGMA (de Leeuw et al., 2015). 607 MAGMA gene-based tests combine *P*-values from multiple SNPs inside a gene to obtain a test

608	statistic for each gene (Z_{gene}), while accounting for incomplete linkage disequilibrium between
609	SNPs. To this end, a list of 18,296 genes and their start- and end-positions, and pre-formatted
610	genotypes, based on 1000G phase 3, were obtained from the MAGMA website (see
611	Supplements). We applied a Bonferroni correction for multiple testing at α = 0.05 / 18,296 =
612	2.733 x 10 ⁻⁶ .
613	It remains difficult to identify which genes are causally involved in ADHD. Fine-mapped
614	Locus Assessment Model of Effector geneS (FLAMES) was recently developed with the goal of
615	predicting the most likely effector genes from GWAS results. FLAMES is a novel framework that
616	combines SNP-to-gene evidence and convergence-based evidence, outputting a single score per
617	gene from fine-mapped GWAS loci. We performed statistical fine-mapping using FINEMAP
618	version 1.4.1 (Benner et al., 2016), and an LD reference panel of 100,000 unrelated UK biobank
619	participants of European descent. Given that the GWAMA contains cohorts that do not belong to
620	the UK biobank we restricted the maximum number of causal variants in a locus modelled by
621	FINEMAP to 1, to avoid overfitting. We ran FLAMES (version 1.0.0) by inputting pathway naïve
622	PoPS scores (Weeks et al., 2023) for our GWAMA, the FUMA defined loci and corresponding
623	fine-mapped credible sets, resulting in a single FLAMES score per gene. Genes with FLAMES
624	scores above 0.05 were interpreted as potential effector genes, as suggested by the FLAMES
625	authors. For more information on FLAMES, and the included functional annotations, see Schipper
626	et al. (2023). Functional annotation and enrichment analysis was done for a set of genes with
627	FLAMES scores above 0.05.

628

629 Enrichment & pathway analyses

630 We performed MAGMA gene-set analyses using the full ADHD_{overall} results. Gene property

631 analysis was performed to test relationships between tissue specific gene expression profiles (See

Supplementary Notes for an overview) and ADHD-gene associations. Next, genes mapped by FUMA, and the set of potential effector genes identified with FLAMES were used in gene-set enrichment analyses. We ran hypergeometric tests using FUMA genes2func to assess if genes of interest are overrepresented in any of the pre-defined gene sets (See Supplemental Notes for all included gene-sets). We used SynGO (Koopmans et al., 2019) v1.2 ("20231201") to test for enrichment in genes encoding for proteins involved in synaptic cellular components and biological pathways. The brain expressed background set was used, containing 18,035 unique genes.

639

640 *Genetic correlations*

We computed genetic correlations between ADHD_{overall} and 49 preselected traits, including cognition and externalizing behaviors, psychopathologies, anthropometric measures, metabolic, and health outcomes (see Supplementary Table 10). Phenotypes were selected based on established hypotheses or were at least nominally significantly (P<0.05) genetically correlated with ADHD_{DIAG2019} (Demontis et al., 2019). Following Bulik-Sullivan et al. (Bulik-Sullivan, Finucane, et al., 2015) we restricted genetic correlations to external phenotypes for which the Z-scores of the LDSC-based h_{SNP}^2 are ≥ 4 .

648

649

- 650
- 651
- 652
- 653
- 654
- 655

656 Acknowledgements

- 657 We very warmly thank all participants, their parents, and teachers for making this study possible.
- 658 The project was supported by the Aggression in Children: Unraveling gene-environment
- 659 interplay to inform Treatment and InterventiON strategies project (ACTION). ACTION received
- 660 funding from the European Union Seventh Framework Program (FP7/2007-2013) under grant
- agreement no 602768. Cohort-specific acknowledgements and funding information are included
- 662 in the Supplementary text.
- 663

664 Ethics & Inclusion Statement

665 This study is the result of a large collaborative effort among multiple clinical and population-666 based cohorts. Researchers and principal investigators (PIs) representing the individual cohorts 667 were involved in the design and execution of the study. Cohort specific GWAS analyses were 668 performed locally, by local researchers. Local researchers and PIs were included as co-authors in 669 consultation with the PIs of each included cohort. Data collections for the cohorts were approved 670 by local ethics committees. Study approval was obtained from the Central Ethics Committee on 671 Research Involving Human Subjects of the VU University Medical Center, Amsterdam (NTR 672 25th of May 2007 and ACTION 2013/41 and 2014.252), an Institutional Review Board certified 673 by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-674 wide Assurance- FWA00017598; IRB/institute codes).

675

676 Competing interests

577 J.A.R.Q. was on the speakers' bureau and/or acted as consultant for Biogen, Idorsia, Casen-

- 678 Recordati, Janssen-Cilag, Novartis, Takeda, Bial, Sincrolab, Neuraxpharm, Novartis, BMS,
- 679 Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel27

680	awards (air tickets + hotel) for taking part in psychiatric meetings from Idorsia, Janssen-Cilag,
681	Rubió, Takeda, Bial and Medice. The Department of Psychiatry chaired by him received
682	unrestricted educational and research support from the following companies in the last 3 years:
683	Exeltis, Idorsia, Janssen- Cilag, Neuraxpharm, Oryzon, Roche, Probitas and Rubió. M.C. has
684	received fees to give talks for TAKEDA and Laboratorios RUBIO. The authors have no other
685	relevant affiliations or financial involvement with any organization or entity with a financial
686	interest in or financial conflict with the subject matter or materials discussed in the manuscript
687	apart from those disclosed.
688	
689	<u>URLs</u>
690	GWAS Catalog: https://www.ebi.ac.uk/gwas/
691	FUMA: <u>https://fuma.ctglab.nl</u>
692	SynGO: <u>https://www.syngoportal.org</u>
693	Summary statistics: TBA
694	
695	Code & Summary Statistics
696	Analysis plan: <u>https://www.action-</u>
697	euproject.eu/sites/default/files/Action%20AGG%20AP%20SOP.pdf
698	Code: -link to follow-
699	Summary Statistics: -link to follow-
700	
701	
702	

703

704

705 <u>References</u>

- Achenbach, T. M., Ivanova, M. Y., & Rescorla, L. A. (2017). Empirically based assessment and
 taxonomy of psychopathology for ages 1¹/₂-90+ years: Developmental, multi-informant, and
 multicultural findings. *Comprehensive Psychiatry*, *79*, 4–18.
- 709 https://doi.org/10.1016/j.comppsych.2017.03.006
- American Psychiatric Association. (2013). *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.*
- 712 Bartels, M., Hendriks, A., Mauri, M., Krapohl, E., Whipp, A., Bolhuis, K., Conde, L. C.,
- Luningham, J., Fung Ip, H., Hagenbeek, F., Roetman, P., Gatej, R., Lamers, A., Nivard, M.,
 van Dongen, J., Lu, Y., Middeldorp, C., van Beijsterveldt, T., Vermeiren, R., ... Boomsma,
- 715 D. I. (2018). Childhood aggression and the co-occurrence of behavioural and emotional
- 716 problems: results across ages 3–16 years from multiple raters in six cohorts in the EU-
- 717 ACTION project. European Child & Adolescent Psychiatry, 27(9), 1105–1121.
- 718 https://doi.org/10.1007/s00787-018-1169-1
- Baselmans, B. M. L., Jansen, R., Ip, H. F., van Dongen, J., Abdellaoui, A., van de Weijer, M. P.,
 Bao, Y., Smart, M., Kumari, M., Willemsen, G., Hottenga, J.-J., Boomsma, D. I., de Geus,
 E. J. C., Nivard, M. G., & Bartels, M. (2019). Multivariate genome-wide analyses of the
 well-being spectrum. *Nature Genetics*, *51*(3), 445–451. https://doi.org/10.1038/s41588-0180320-8
- Benner, C., Spencer, C. C. A., Havulinna, A. S., Salomaa, V., Ripatti, S., & Pirinen, M. (2016).
 FINEMAP: efficient variable selection using summary data from genome-wide association studies. *Bioinformatics*, *32*(10), 1493–1501. https://doi.org/10.1093/bioinformatics/btw018
- Boomsma, D. I. (2015). Aggression in children: unravelling the interplay of genes and
 environment through (epi)genetics and metabolomics. *Journal of Pediatric and Neonatal Individualized Medicine*, 4(2), e040251. https://doi.org/https://doi.org/10.7363/040251
- Bulik-Sullivan, B. K., Finucane, H. K., Anttila, V., Gusev, A., Day, F. R., Loh, P.-R., Duncan,
 L., Perry, J. R. B., Patterson, N., Robinson, E. B., Daly, M. J., Price, A. L., & Neale, B. M.
 (2015). An atlas of genetic correlations across human diseases and traits. *Nature Genetics*,
- 733 47(11), 1236–1241. https://doi.org/10.1038/ng.3406
- Bulik-Sullivan, B. K., Loh, P.-R., Finucane, H. K., Ripke, S., Yang, J., Patterson, N., Daly, M. J.,
 Price, A. L., & Neale, B. M. (2015). LD Score regression distinguishes confounding from
 polygenicity in genome-wide association studies. *Nature Genetics*, 47(3), 291–295.
 https://doi.org/10.1038/ng.3211
- Caci, H., Asherson, P., Donfrancesco, R., Faraone, S. V., Hervas, A., Fitzgerald, M., & Döpfner,
 M. (2015). Daily life impairments associated with childhood/adolescent attentiondeficit/hyperactivity disorder as recalled by adults: results from the European Lifetime
 Impairment Survey. *CNS Spectrums*, 20(2), 112–121.
- 742 https://doi.org/10.1017/S1092852914000078
- Caci, H., Doepfner, M., Asherson, P., Donfrancesco, R., Faraone, S. V., Hervas, A., & Fitzgerald,
 M. (2014). Daily life impairments associated with self-reported childhood/adolescent
- attention-deficit/hyperactivity disorder and experiences of diagnosis and treatment: Results

746 from the European Lifetime Impairment Survey. European Psychiatry, 29(5), 316-323. 747 https://doi.org/10.1016/j.eurpsy.2013.10.007 748 de Leeuw, C. A., Mooij, J. M., Heskes, T., & Posthuma, D. (2015). MAGMA: Generalized Gene-749 Set Analysis of GWAS Data. PLOS Computational Biology, 11(4), e1004219. 750 https://doi.org/10.1371/journal.pcbi.1004219 751 Demontis, D., Walters, G. B., Athanasiadis, G., Walters, R., Therrien, K., Nielsen, T. T., 752 Farajzadeh, L., Voloudakis, G., Bendl, J., Zeng, B., Zhang, W., Grove, J., Als, T. D., Duan, 753 J., Satterstrom, F. K., Bybjerg-Grauholm, J., Bækved-Hansen, M., Gudmundsson, O. O., 754 Magnusson, S. H., ... Børglum, A. D. (2023). Genome-wide analyses of ADHD identify 27 755 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature 756 Genetics, 55(2), 198-208. https://doi.org/10.1038/s41588-022-01285-8 757 Demontis, D., Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E., Baldursson, G., 758 Belliveau, R., Bybjerg-Grauholm, J., Bækvad-Hansen, M., Cerrato, F., Chambert, K., 759 Churchhouse, C., Dumont, A., Eriksson, N., Gandal, M., Goldstein, J. I., Grasby, K. L., 760 Grove, J., ... Neale, B. M. (2019). Discovery of the first genome-wide significant risk loci 761 for attention deficit/hyperactivity disorder. Nature Genetics, 51(1), 63-75. 762 https://doi.org/10.1038/s41588-018-0269-7 763 Derks, E. M., Hudziak, J. J., Dolan, C. V., van Beijsterveldt, T. C. E. M., Verhulst, F. C., & 764 Boomsma, D. I. (2008). Genetic and Environmental Influences on the Relation Between 765 Attention Problems and Attention Deficit Hyperactivity Disorder. *Behavior Genetics*, 38(1), 766 11-23. https://doi.org/10.1007/s10519-007-9178-8 767 Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, 768 J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015). Attention-769 deficit/hyperactivity disorder. Nature Reviews Disease Primers, 1(1), 15020. 770 https://doi.org/10.1038/nrdp.2015.20 771 Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. 772 H., Philipsen, A., Polanczyk, G. V., Rubia, K., Sibley, M. H., & Buitelaar, J. K. (2024). 773 Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers, 10(1), 11. 774 https://doi.org/10.1038/s41572-024-00495-0 775 Faraone, S. V., Biederman, J., & Mick, E. (2006). The age-dependent decline of attention deficit 776 hyperactivity disorder: a meta-analysis of follow-up studies. *Psychological Medicine*, 36(2), 777 159-165. https://doi.org/10.1017/S003329170500471X 778 Faraone, S. V., & Larsson, H. (2019). Genetics of attention deficit hyperactivity disorder. 779 Molecular Psychiatry, 24(4), 562–575. https://doi.org/10.1038/s41380-018-0070-0 780 Goodman, R. (2001). Psychometric Properties of the Strengths and Difficulties Questionnaire. 781 Journal of the American Academy of Child & Adolescent Psychiatry, 40(11), 1337–1345. 782 https://doi.org/10.1097/00004583-200111000-00015 783 Grotzinger, A. D., Rhemtulla, M., de Vlaming, R., Ritchie, S. J., Mallard, T. T., Hill, W. D., Ip, 784 H. F., Marioni, R. E., McIntosh, A. M., Deary, I. J., Koellinger, P. D., Harden, K. P., Nivard, 785 M. G., & Tucker-Drob, E. M. (2019). Genomic structural equation modelling provides 786 insights into the multivariate genetic architecture of complex traits. Nature Human 787 Behaviour, 3(5), 513-525. https://doi.org/10.1038/s41562-019-0566-x 788 Ip, H. F., van der Laan, C. M., Krapohl, E. M. L., Brikell, I., Sánchez-Mora, C., Nolte, I. M., St 789 Pourcain, B., Bolhuis, K., Palviainen, T., Zafarmand, H., Colodro-Conde, L., Gordon, S., 790 Zayats, T., Aliev, F., Jiang, C., Wang, C. A., Saunders, G., Karhunen, V., Hammerschlag, A. 791 R., ... Boomsma, D. I. (2021). Genetic association study of childhood aggression across

- 792 raters, instruments, and age. Translational Psychiatry, 11(1), 413. 793 https://doi.org/10.1038/s41398-021-01480-x 794 Kan, K.-J., Dolan, C. V., Nivard, M. G., Middeldorp, C. M., van Beijsterveldt, C. E. M., 795 Willemsen, G., & Boomsma, D. I. (2013). Genetic and Environmental Stability in Attention 796 Problems Across the Lifespan: Evidence From the Netherlands Twin Register. Journal of 797 the American Academy of Child & Adolescent Psychiatry, 52(1), 12–25. 798 https://doi.org/10.1016/j.jaac.2012.10.009 799 Kan, K.-J., van Beijsterveldt, C. E. M., Bartels, M., & Boomsma, D. I. (2014). Assessing Genetic 800 Influences on Behavior: Informant and Context Dependency as Illustrated by the Analysis of 801 Attention Problems. Behavior Genetics, 44(4), 326–336. https://doi.org/10.1007/s10519-802 014-9657-7 803 Koopmans, F., van Nierop, P., Andres-Alonso, M., Byrnes, A., Cijsouw, T., Coba, M. P., 804 Cornelisse, L. N., Farrell, R. J., Goldschmidt, H. L., Howrigan, D. P., Hussain, N. K., Imig, 805 C., de Jong, A. P. H., Jung, H., Kohansalnodehi, M., Kramarz, B., Lipstein, N., Lovering, R. 806 C., MacGillavry, H., ... Verhage, M. (2019). SynGO: An Evidence-Based, Expert-Curated 807 Knowledge Base for the Synapse. Neuron, 103(2), 217-234.e4. 808 https://doi.org/10.1016/j.neuron.2019.05.002 809 Larsson, H., Anckarsater, H., Råstam, M., Chang, Z., & Lichtenstein, P. (2012). Childhood 810 attention-deficit hyperactivity disorder as an extreme of a continuous trait: a quantitative 811 genetic study of 8,500 twin pairs. Journal of Child Psychology and Psychiatry, 53(1), 73-812 80. https://doi.org/10.1111/j.1469-7610.2011.02467.x 813 Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011). Prospective association of 814 childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and 815 abuse/dependence: A meta-analytic review. Clinical Psychology Review, 31(3), 328-341. 816 https://doi.org/10.1016/j.cpr.2011.01.006 817 Levy, F., Hay, D. A., McStephen, M., Wood, C., & Waldman, I. (1997). Attention-Deficit 818 Hyperactivity Disorder: A Category or a Continuum? Genetic Analysis of a Large-Scale 819 Twin Study. Journal of the American Academy of Child & Adolescent Psychiatry, 36(6), 820 737-744. https://doi.org/10.1097/00004583-199706000-00009 821 Liu, Q., Cirulli, E. T., Han, Y., Yao, S., Liu, S., & Zhu, Q. (2015). Systematic assessment of 822 imputation performance using the 1000 Genomes reference panels. Briefings in 823 Bioinformatics, 16(4), 549–562. https://doi.org/10.1093/bib/bbu035 824 Marees, A. T., Smit, D. J. A., Ong, J.-S., MacGregor, S., An, J., Denys, D., Vorspan, F., van den 825 Brink, W., & Derks, E. M. (2020). Potential influence of socioeconomic status on genetic 826 correlations between alcohol consumption measures and mental health. Psychological 827 Medicine, 50(3), 484-498. https://doi.org/10.1017/S0033291719000357 828 Merwood, A., Greven, C. U., Price, T. S., Rijsdijk, F., Kuntsi, J., McLoughlin, G., Larsson, H., & 829 Asherson, P. J. (2013). Different heritabilities but shared etiological influences for parent, 830 teacher and self-ratings of ADHD symptoms: an adolescent twin study. Psychological 831 Medicine, 43(9), 1973–1984. https://doi.org/10.1017/S0033291712002978 832 Middeldorp, C. M., Felix, J. F., Mahajan, A., & McCarthy, M. I. (2019). The Early Growth 833 Genetics (EGG) and EArly Genetics and Lifecourse Epidemiology (EAGLE) consortia: 834 design, results and future prospects. European Journal of Epidemiology, 34(3), 279-300. 835 https://doi.org/10.1007/s10654-019-00502-9 836 Middeldorp, C. M., Hammerschlag, A. R., Ouwens, K. G., Groen-Blokhuis, M. M., St. Pourcain, 837 B., Greven, C. U., Pappa, I., Tiesler, C. M. T., Ang, W., Nolte, I. M., Vilor-Tejedor, N., 838 Bacelis, J., Ebejer, J. L., Zhao, H., Davies, G. E., Ehli, E. A., Evans, D. M., Fedko, I. O.,
 - 31

839	Guxens, M., Boomsma, D. I. (2016). A Genome-Wide Association Meta-Analysis of
840	Attention-Deficit/Hyperactivity Disorder Symptoms in Population-Based Pediatric Cohorts.
841	Journal of the American Academy of Child & Adolescent Psychiatry, 55(10), 896-905.e6.
842	https://doi.org/10.1016/j.jaac.2016.05.025
843	Minică, C. C., Dolan, C. V, Kampert, M. M. D., Boomsma, D. I., & Vink, J. M. (2015).
844	Sandwich corrected standard errors in family-based genome-wide association studies.
845	European Journal of Human Genetics, 23(3), 388–394. https://doi.org/10.1038/ejhg.2014.94
846	Schipper, M., de Leeuw, C. A., Maciel, B. A. P. C., Wightman, D. P., Hubers, N., Boomsma, D.
847	I., O'Donovan, M. C., & Posthuma, D. (2023). A framework for accurate prediction of
848	effector genes in genetic loci for complex traits. MedRxiv.
849	Tucker, G., Loh, PR., MacLeod, I. M., Hayes, B. J., Goddard, M. E., Berger, B., & Price, A. L.
850	(2015). Two-Variance-Component Model Improves Genetic Prediction in Family Datasets.
851	The American Journal of Human Genetics, 97(5), 677–690.
852	https://doi.org/10.1016/j.ajhg.2015.10.002
853	Wang, X., Walker, A., Revez, J. A., Ni, G., Adams, M. J., McIntosh, A. M., Visscher, P. M.,
854	Wray, N. R., Wray, N. R., Ripke, S., Mattheisen, M., Trzaskowski, M., Byrne, E. M.,
855	Abdellaoui, A., Adams, M. J., Agerbo, E., Air, T. M., Andlauer, T. F. M., Bacanu, SA.,
856	Sullivan, P. F. (2023). Polygenic risk prediction: why and when out-of-sample prediction R2
857	can exceed SNP-based heritability. The American Journal of Human Genetics, 110(7),
858	1207-1215. https://doi.org/10.1016/j.ajhg.2023.06.006
859	Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017). Functional mapping and
860	annotation of genetic associations with FUMA. Nature Communications, 8(1), 1826.
861	https://doi.org/10.1038/s41467-017-01261-5
862	Weeks, E. M., Ulirsch, J. C., Cheng, N. Y., Trippe, B. L., Fine, R. S., Miao, J., Patwardhan, T.
863	A., Kanai, M., Nasser, J., Fulco, C. P., Tashman, K. C., Aguet, F., Li, T., Ordovas-
864	Montanes, J., Smillie, C. S., Biton, M., Shalek, A. K., Ananthakrishnan, A. N., Xavier, R. J.,
865	Finucane, H. K. (2023). Leveraging polygenic enrichments of gene features to predict
866	genes underlying complex traits and diseases. Nature Genetics, 55(8), 1267–1276.
867	https://doi.org/10.1038/s41588-023-01443-6